In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract
The incidence of bleeding related to stress ulcers is reduced in critically ill patients in whom gut decontamination has been performed; this may be a result of suppression of Helicobacter pylori infection. We determined the susceptibility of H. pylori to the applied antibiotics. In nine of 10 criti...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2000-11, Vol.46 (5), p.803-805 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 805 |
|---|---|
| container_issue | 5 |
| container_start_page | 803 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 46 |
| creator | van der Voort, Peter H. J. van der Hulst, René W. M. Zandstra, Durk F. van der Ende, Arie Geraedts, Alfons A. M. Tytgat, Guido N. J. |
| description | The incidence of bleeding related to stress ulcers is reduced in critically ill patients in whom gut decontamination has been performed; this may be a result of suppression of Helicobacter pylori infection. We determined the susceptibility of H. pylori to the applied antibiotics. In nine of 10 critically ill patients (using intravenous cefotaxime and topical polymyxin, tobramycin and amphotericin B (PTA) given by nasogastric tube) and all six volunteers (using PTA alone), H. pylori was suppressed as long as the topical antibiotics were ingested. The in vitro studies revealed that all strains were susceptible to cefotaxime and tobramycin. The strains were not susceptible to polymyxin or amphotericin B. |
| doi_str_mv | 10.1093/jac/46.5.803 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72392888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17757431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c449t-70586e41672b35e5312ebd35d51631905f348a2b43473f0663a0efc36aae0b833</originalsourceid><addsrcrecordid>eNqFkk9v1DAQxSMEokvhxhlZIHFqtv7v5IgK7Faq4AICcbEcZwJekji1nRX7Rfi8ON1VkbhwsuT5vTfjeS6K5wSvCa7Z5c7YSy7XYl1h9qBYES5xSXFNHhYrzLAoFRfsrHgS4w5jLIWsHhdnhGBJKaar4vf1iPYuBY_iHC1MyTWud-mAfIe20DvrG2MTBDQdeh8cSv4CmbFFbpHtF9U0BYjR-RE1h6WW3OBs8I0zfURzhDs2Qg82uT2gFqwfkxncaNIiyn3Sj3ztvkO8A1LIDZ8Wj7qsh2en87z4_P7dp6ttefNxc3315qa0nNepVFhUEjiRijZMgGCEQtMy0QoiGamx6BivDG0444p1WEpmMHSWSWMANxVj58Xro-8U_O2cJ9CDy2voezOCn6NWlNW0qqr_gkQpoTgjGXz5D7jzcxjzIzQlSkqsKM_QxRHKi4oxQKen4AYTDppgvaSqc6qaSy10TjXjL06eczNA-xc-xZiBVyfARGv6LpjRunjPqTr_h8WmPFIuJvh1XzXhp5aKKaG3X79pWW--vN1sPmjO_gArS7p7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217660724</pqid></control><display><type>article</type><title>In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Free Full-Text Journals in Chemistry</source><creator>van der Voort, Peter H. J. ; van der Hulst, René W. M. ; Zandstra, Durk F. ; van der Ende, Arie ; Geraedts, Alfons A. M. ; Tytgat, Guido N. J.</creator><creatorcontrib>van der Voort, Peter H. J. ; van der Hulst, René W. M. ; Zandstra, Durk F. ; van der Ende, Arie ; Geraedts, Alfons A. M. ; Tytgat, Guido N. J.</creatorcontrib><description>The incidence of bleeding related to stress ulcers is reduced in critically ill patients in whom gut decontamination has been performed; this may be a result of suppression of Helicobacter pylori infection. We determined the susceptibility of H. pylori to the applied antibiotics. In nine of 10 critically ill patients (using intravenous cefotaxime and topical polymyxin, tobramycin and amphotericin B (PTA) given by nasogastric tube) and all six volunteers (using PTA alone), H. pylori was suppressed as long as the topical antibiotics were ingested. The in vitro studies revealed that all strains were susceptible to cefotaxime and tobramycin. The strains were not susceptible to polymyxin or amphotericin B.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/46.5.803</identifier><identifier>PMID: 11062202</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Administration, Topical ; Amphotericin B - pharmacology ; Amphotericin B - therapeutic use ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Cefotaxime - pharmacology ; Cefotaxime - therapeutic use ; Cephalosporins - pharmacology ; Cephalosporins - therapeutic use ; Decontamination - methods ; Digestive System - drug effects ; Drug Therapy, Combination - pharmacology ; Drug Therapy, Combination - therapeutic use ; Helicobacter Infections - drug therapy ; Helicobacter Infections - immunology ; Helicobacter pylori ; Helicobacter pylori - drug effects ; Helicobacter pylori - immunology ; Humans ; Medical sciences ; Microbial Sensitivity Tests - methods ; Pharmacology. Drug treatments ; Polymyxins - pharmacology ; Polymyxins - therapeutic use ; Tobramycin - pharmacology ; Tobramycin - therapeutic use</subject><ispartof>Journal of antimicrobial chemotherapy, 2000-11, Vol.46 (5), p.803-805</ispartof><rights>2001 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Nov 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c449t-70586e41672b35e5312ebd35d51631905f348a2b43473f0663a0efc36aae0b833</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=790913$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11062202$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van der Voort, Peter H. J.</creatorcontrib><creatorcontrib>van der Hulst, René W. M.</creatorcontrib><creatorcontrib>Zandstra, Durk F.</creatorcontrib><creatorcontrib>van der Ende, Arie</creatorcontrib><creatorcontrib>Geraedts, Alfons A. M.</creatorcontrib><creatorcontrib>Tytgat, Guido N. J.</creatorcontrib><title>In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>The incidence of bleeding related to stress ulcers is reduced in critically ill patients in whom gut decontamination has been performed; this may be a result of suppression of Helicobacter pylori infection. We determined the susceptibility of H. pylori to the applied antibiotics. In nine of 10 critically ill patients (using intravenous cefotaxime and topical polymyxin, tobramycin and amphotericin B (PTA) given by nasogastric tube) and all six volunteers (using PTA alone), H. pylori was suppressed as long as the topical antibiotics were ingested. The in vitro studies revealed that all strains were susceptible to cefotaxime and tobramycin. The strains were not susceptible to polymyxin or amphotericin B.</description><subject>Administration, Topical</subject><subject>Amphotericin B - pharmacology</subject><subject>Amphotericin B - therapeutic use</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Cefotaxime - pharmacology</subject><subject>Cefotaxime - therapeutic use</subject><subject>Cephalosporins - pharmacology</subject><subject>Cephalosporins - therapeutic use</subject><subject>Decontamination - methods</subject><subject>Digestive System - drug effects</subject><subject>Drug Therapy, Combination - pharmacology</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Helicobacter Infections - drug therapy</subject><subject>Helicobacter Infections - immunology</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - drug effects</subject><subject>Helicobacter pylori - immunology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymyxins - pharmacology</subject><subject>Polymyxins - therapeutic use</subject><subject>Tobramycin - pharmacology</subject><subject>Tobramycin - therapeutic use</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk9v1DAQxSMEokvhxhlZIHFqtv7v5IgK7Faq4AICcbEcZwJekji1nRX7Rfi8ON1VkbhwsuT5vTfjeS6K5wSvCa7Z5c7YSy7XYl1h9qBYES5xSXFNHhYrzLAoFRfsrHgS4w5jLIWsHhdnhGBJKaar4vf1iPYuBY_iHC1MyTWud-mAfIe20DvrG2MTBDQdeh8cSv4CmbFFbpHtF9U0BYjR-RE1h6WW3OBs8I0zfURzhDs2Qg82uT2gFqwfkxncaNIiyn3Sj3ztvkO8A1LIDZ8Wj7qsh2en87z4_P7dp6ttefNxc3315qa0nNepVFhUEjiRijZMgGCEQtMy0QoiGamx6BivDG0444p1WEpmMHSWSWMANxVj58Xro-8U_O2cJ9CDy2voezOCn6NWlNW0qqr_gkQpoTgjGXz5D7jzcxjzIzQlSkqsKM_QxRHKi4oxQKen4AYTDppgvaSqc6qaSy10TjXjL06eczNA-xc-xZiBVyfARGv6LpjRunjPqTr_h8WmPFIuJvh1XzXhp5aKKaG3X79pWW--vN1sPmjO_gArS7p7</recordid><startdate>20001101</startdate><enddate>20001101</enddate><creator>van der Voort, Peter H. J.</creator><creator>van der Hulst, René W. M.</creator><creator>Zandstra, Durk F.</creator><creator>van der Ende, Arie</creator><creator>Geraedts, Alfons A. M.</creator><creator>Tytgat, Guido N. J.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20001101</creationdate><title>In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract</title><author>van der Voort, Peter H. J. ; van der Hulst, René W. M. ; Zandstra, Durk F. ; van der Ende, Arie ; Geraedts, Alfons A. M. ; Tytgat, Guido N. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c449t-70586e41672b35e5312ebd35d51631905f348a2b43473f0663a0efc36aae0b833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Administration, Topical</topic><topic>Amphotericin B - pharmacology</topic><topic>Amphotericin B - therapeutic use</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Cefotaxime - pharmacology</topic><topic>Cefotaxime - therapeutic use</topic><topic>Cephalosporins - pharmacology</topic><topic>Cephalosporins - therapeutic use</topic><topic>Decontamination - methods</topic><topic>Digestive System - drug effects</topic><topic>Drug Therapy, Combination - pharmacology</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Helicobacter Infections - drug therapy</topic><topic>Helicobacter Infections - immunology</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - drug effects</topic><topic>Helicobacter pylori - immunology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymyxins - pharmacology</topic><topic>Polymyxins - therapeutic use</topic><topic>Tobramycin - pharmacology</topic><topic>Tobramycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van der Voort, Peter H. J.</creatorcontrib><creatorcontrib>van der Hulst, René W. M.</creatorcontrib><creatorcontrib>Zandstra, Durk F.</creatorcontrib><creatorcontrib>van der Ende, Arie</creatorcontrib><creatorcontrib>Geraedts, Alfons A. M.</creatorcontrib><creatorcontrib>Tytgat, Guido N. J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van der Voort, Peter H. J.</au><au>van der Hulst, René W. M.</au><au>Zandstra, Durk F.</au><au>van der Ende, Arie</au><au>Geraedts, Alfons A. M.</au><au>Tytgat, Guido N. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2000-11-01</date><risdate>2000</risdate><volume>46</volume><issue>5</issue><spage>803</spage><epage>805</epage><pages>803-805</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>The incidence of bleeding related to stress ulcers is reduced in critically ill patients in whom gut decontamination has been performed; this may be a result of suppression of Helicobacter pylori infection. We determined the susceptibility of H. pylori to the applied antibiotics. In nine of 10 critically ill patients (using intravenous cefotaxime and topical polymyxin, tobramycin and amphotericin B (PTA) given by nasogastric tube) and all six volunteers (using PTA alone), H. pylori was suppressed as long as the topical antibiotics were ingested. The in vitro studies revealed that all strains were susceptible to cefotaxime and tobramycin. The strains were not susceptible to polymyxin or amphotericin B.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>11062202</pmid><doi>10.1093/jac/46.5.803</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2000-11, Vol.46 (5), p.803-805 |
| issn | 0305-7453 1460-2091 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72392888 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Free Full-Text Journals in Chemistry |
| subjects | Administration, Topical Amphotericin B - pharmacology Amphotericin B - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Cefotaxime - pharmacology Cefotaxime - therapeutic use Cephalosporins - pharmacology Cephalosporins - therapeutic use Decontamination - methods Digestive System - drug effects Drug Therapy, Combination - pharmacology Drug Therapy, Combination - therapeutic use Helicobacter Infections - drug therapy Helicobacter Infections - immunology Helicobacter pylori Helicobacter pylori - drug effects Helicobacter pylori - immunology Humans Medical sciences Microbial Sensitivity Tests - methods Pharmacology. Drug treatments Polymyxins - pharmacology Polymyxins - therapeutic use Tobramycin - pharmacology Tobramycin - therapeutic use |
| title | In vitro susceptibility of Helicobacter pylori to, and in vivo suppression by, antimicrobials used in selective decontamination of the digestive tract |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A21%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20susceptibility%20of%20Helicobacter%20pylori%20to,%20and%20in%20vivo%20suppression%20by,%20antimicrobials%20used%20in%20selective%20decontamination%20of%20the%20digestive%20tract&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=van%20der%20Voort,%20Peter%20H.%20J.&rft.date=2000-11-01&rft.volume=46&rft.issue=5&rft.spage=803&rft.epage=805&rft.pages=803-805&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/46.5.803&rft_dat=%3Cproquest_cross%3E17757431%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217660724&rft_id=info:pmid/11062202&rfr_iscdi=true |